Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia

Bio-Path Holdings Inc BPTH reported interim data from Stage 2 of the company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for acute myeloid leukemia (AML)

Prexigebersen continues to be well-tolerated and has shown compelling efficacy results in two reporting cohorts, including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, exceeding outcomes with frontline therapy. 

Fourteen newly diagnosed patients were evaluable in Cohort 1 and treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy. 

Twelve of the fourteen evaluable patients (86%) achieved complete remission (CR/CRi), and two (14%) achieved partial remission (PR). 

In total, 100% of the evaluable patients had a response to treatment.

The complete remission rate (CR/CRi) of (86%) for the evaluable patients in Cohort 1 is significantly higher than complete remission (CR/CRi) rates (62%) for newly diagnosed patients treated with the frontline combination of decitabine and venetoclax. 

Fourteen refractory/relapsed evaluable AML patients in Cohort 2 were treated with at least one cycle of the prexigebersen, decitabine, and venetoclax combination therapy. 

Eight of the fourteen evaluable patients (57%) achieved complete remission (CR/CRi), two (14%) achieved partial remission (PR), and three (22%) achieved stable disease. 

In total, 93% of the evaluable patients had a response to treatment. The complete remission rate (CR/CRi) of (57%) for the evaluable refractory and relapsed patients in Cohort 2 is significantly higher than the complete remission (CR/CRi) rate (21%) for refractory/relapsed patients treated with the combination treatment of decitabine and venetoclax. 

Price Action: BPTH shares are down 7.57% at $0.98 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!